Paloma Partners’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-352
| Closed | -$223K | – | 148 |
|
|
2025
Q1 | $223K | Buy |
+352
| New | +$242K | 0.03% | 109 |
|
|
2024
Q4 | – | Sell |
-625
| Closed | -$657K | – | 919 |
|
|
2024
Q3 | $657K | Buy |
625
+62
| +11% | +$69K | 0.02% | 535 |
|
|
2024
Q2 | $592K | Sell |
563
-1,683
| -75% | -$1.63M | 0.02% | 674 |
|
|
2024
Q1 | $2.16M | Buy |
2,246
+1,197
| +114% | +$1.14M | 0.11% | 228 |
|
|
2023
Q4 | $921K | Buy |
+1,049
| New | +$864K | 0.03% | 435 |
|
|
2023
Q3 | – | Sell |
-324
| Closed | -$233K | – | 891 |
|
|
2023
Q2 | $233K | Buy |
324
+175
| +117% | +$135K | 0.01% | 581 |
|
|
2023
Q1 | $122K | Buy |
+149
| New | +$112K | ﹤0.01% | 671 |
|
|
2022
Q4 | – | Sell |
-1,365
| Closed | -$940K | – | 1127 |
|
|
2022
Q3 | $940K | Buy |
+1,365
| New | +$859K | 0.04% | 337 |
|
|
2022
Q2 | – | Sell |
-781
| Closed | -$546K | – | 1640 |
|
|
2022
Q1 | $546K | Buy |
781
+441
| +130% | +$279K | 0.02% | 708 |
|
|
2021
Q4 | $215K | Sell |
340
-8,511
| -96% | -$5.23M | ﹤0.01% | 1570 |
|
|
2021
Q3 | $5.36M | Buy |
8,851
+7,315
| +476% | +$4.54M | 0.13% | 98 |
|
|
2021
Q2 | $858K | Sell |
1,536
-8,067
| -84% | -$4.09M | 0.02% | 717 |
|
|
2021
Q1 | $4.54M | Buy |
+9,603
| New | +$4.68M | 0.1% | 171 |
|
|
2020
Q2 | – | Sell |
-491
| Closed | -$240K | – | 2204 |
|
|
2020
Q1 | $240K | Sell |
491
-1,328
| -73% | -$548K | 0.01% | 812 |
|
|
2019
Q4 | $683K | Buy |
1,819
+702
| +63% | +$236K | 0.01% | 1190 |
|
|
2019
Q3 | $310K | Buy |
+1,117
| New | +$331K | 0.01% | 1504 |
|
|
2019
Q2 | – | Sell |
-1,892
| Closed | -$630K | – | 2100 |
|
|
2019
Q1 | $777K | Buy |
+1,892
| New | +$779K | 0.02% | 854 |
|
|
2018
Q4 | – | Sell |
-2,965
| Closed | -$1.09M | – | 1696 |
|
|
2018
Q3 | $1.2M | Buy |
+2,965
| New | +$1.13M | 0.02% | 663 |
|
|
2018
Q2 | – | Sell |
-7,301
| Closed | -$2.28M | – | 2104 |
|
|
2018
Q1 | $2.51M | Buy |
7,301
+3,056
| +72% | +$1.06M | 0.04% | 452 |
|
|
2017
Q4 | $1.6M | Buy |
+4,245
| New | +$1.72M | 0.02% | 789 |
|
|
2017
Q3 | – | Sell |
-832
| Closed | -$396K | – | 2370 |
|
|
2017
Q2 | $409K | Buy |
+832
| New | +$364K | ﹤0.01% | 1653 |
|
|
2017
Q1 | – | Sell |
-30,067
| Closed | -$11.1M | – | 2194 |
|
|
2016
Q4 | $11M | Buy |
30,067
+14,385
| +92% | +$5.47M | 0.11% | 107 |
|
|
2016
Q3 | $6.3M | Buy |
15,682
+9,257
| +144% | +$3.71M | 0.08% | 150 |
|
|
2016
Q2 | $2.24M | Buy |
6,425
+1,839
| +40% | +$708K | 0.02% | 659 |
|
|
2016
Q1 | $1.65M | Sell |
4,586
-3,691
| -45% | -$1.52M | 0.03% | 576 |
|
|
2015
Q4 | $4.49M | Sell |
8,277
-85,285
| -91% | -$46.2M | 0.12% | 142 |
|
|
2015
Q3 | $43.5M | Buy |
93,562
+90,425
| +2,883% | +$48.6M | 1.01% | 13 |
|
|
2015
Q2 | $1.6M | Buy |
+3,137
| New | +$1.53M | 0.03% | 543 |
|
|
2015
Q1 | – | Sell |
-740
| Closed | -$304K | – | 1393 |
|
|
2014
Q4 | $304K | Sell |
740
-10,078
| -93% | -$3.96M | 0.01% | 846 |
|
|
2014
Q3 | $3.9M | Buy |
10,818
+5,701
| +111% | +$1.91M | 0.18% | 124 |
|
|
2014
Q2 | $1.45M | Sell |
5,117
-2,134
| -29% | -$632K | 0.06% | 281 |
|
|
2014
Q1 | $2.18M | Buy |
+7,251
| New | +$2.23M | 0.14% | 146 |
|
|
2013
Q4 | – | Sell |
-23,622
| Closed | -$7.39M | – | 1168 |
|
|
2013
Q3 | $7.39M | Buy |
23,622
+10,220
| +76% | +$2.69M | 0.29% | 57 |
|
|
2013
Q2 | $3.01M | Buy |
+13,402
| New | +$3.12M | 0.17% | 122 |
|
Other funds holding REGN
Paloma Partners's REGN Position: Q2 2025 in Review
Paloma Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 352 shares — an estimated $223K sold.
Paloma Partners first reported a position in REGN in Q2 2013 and held it in 34 quarters. The position peaked at $43.5M in Q3 2015. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.
- Paloma Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- Paloma Partners sold 352 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $223K.
- Paloma Partners first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 34 quarters.
- Paloma Partners's Regeneron Pharmaceuticals position peaked at $43.5M in Q3 2015.
- 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.
Based on Paloma Partners's 13F filing for Q2 2025, filed 14 Aug 2025.